RedHill Biopharma Ltd. (RDHL)

7.26
0.01 0.14
NASDAQ : Health Technology
Prev Close 7.25
Open 7.21
Day Low/High 7.10 / 7.38
52 Wk Low/High 5.13 / 9.57
Volume 12.97K
Avg Volume 71.30K
Exchange NASDAQ
Shares Outstanding 28.37M
Market Cap 206.78M
EPS -1.70
P/E Ratio 42.65
Div & Yield N.A. (N.A)

Latest News

3 Small-Caps That Look Like Bargains at Current Trading Levels

3 Small-Caps That Look Like Bargains at Current Trading Levels
RDHL Crosses Above Key Moving Average Level

RDHL Crosses Above Key Moving Average Level
2 Key 'Rules' When Investing in Biotech Stocks

2 Key 'Rules' When Investing in Biotech Stocks

Remembering these 'rules of the road' is vital in this highly volatile space.

How I Invest In Biotech Stocks

How I Invest In Biotech Stocks

Here's two 'rules of the road' when investing in this highly volatile space.

RedHill Biopharma Announces Two Oral Presentations On BEKINDA® 24 Mg For Acute Gastroenteritis At The SAEM 2018 Annual Meeting

RedHill Biopharma Announces Two Oral Presentations On BEKINDA® 24 Mg For Acute Gastroenteritis At The SAEM 2018 Annual Meeting

RedHill Biopharma Announces DDW 2018 Poster Of Distinction On Positive Phase II Results With BEKINDA® For IBS-D

RedHill Biopharma Announces DDW 2018 Poster Of Distinction On Positive Phase II Results With BEKINDA® For IBS-D

RedHill Biopharma To Present At H.C. Wainwright Annual Global Life Sciences Conference

RedHill Biopharma To Present At H.C. Wainwright Annual Global Life Sciences Conference

RedHill Biopharma Announces Poster Presentation On New Potential Therapeutic Applications Of RHB-107 At The AACR 2018 Annual Meeting

RedHill Biopharma Announces Poster Presentation On New Potential Therapeutic Applications Of RHB-107 At The AACR 2018 Annual Meeting

RedHill Biopharma Provides Fourth Quarter And Full-Year 2017 Investor Update

RedHill Biopharma Provides Fourth Quarter And Full-Year 2017 Investor Update

RedHill Biopharma To Host Fourth Quarter And Full-Year 2017 Financial Results Conference Call On February 22, 2018

RedHill Biopharma To Host Fourth Quarter And Full-Year 2017 Financial Results Conference Call On February 22, 2018

RedHill Biopharma To Present At BIO CEO & Investor Conference

RedHill Biopharma To Present At BIO CEO & Investor Conference

RedHill Biopharma And Express Scripts Subsidiary Inside Rx Add EnteraGam® To Savings Program For Uninsured Or Underinsured Patients

RedHill Biopharma And Express Scripts Subsidiary Inside Rx Add EnteraGam® To Savings Program For Uninsured Or Underinsured Patients

RedHill Biopharma Announces Final Results From Phase II Study With BEKINDA® For IBS-D

RedHill Biopharma Announces Final Results From Phase II Study With BEKINDA® For IBS-D

RedHill Biopharma Announces Initiation Of Phase IIa Study With ABC294640 (YELIVA®) For Cholangiocarcinoma At Mayo Clinic And MD Anderson

RedHill Biopharma Announces Initiation Of Phase IIa Study With ABC294640 (YELIVA®) For Cholangiocarcinoma At Mayo Clinic And MD Anderson

RedHill Biopharma Provides 2017 Year-End Business Update

RedHill Biopharma Provides 2017 Year-End Business Update

RedHill Biopharma Announces Closing Of Public Offering Of Its American Depositary Shares

RedHill Biopharma Announces Closing Of Public Offering Of Its American Depositary Shares

RedHill Biopharma Reports 2017 Third Quarter Financial Results

RedHill Biopharma Reports 2017 Third Quarter Financial Results

RedHill Biopharma Announces Last Patient Enrolled In The Phase III Study With RHB-104 For Crohn's Disease

RedHill Biopharma Announces Last Patient Enrolled In The Phase III Study With RHB-104 For Crohn's Disease

RedHill Biopharma Prices Public Offering Of Its American Depositary Shares

RedHill Biopharma Prices Public Offering Of Its American Depositary Shares

RedHill Biopharma Announces Proposed Public Offering Of Its American Depositary Shares

RedHill Biopharma Announces Proposed Public Offering Of Its American Depositary Shares

RedHill Biopharma To Host Third Quarter 2017 Financial Results Conference Call On November 13, 2017

RedHill Biopharma To Host Third Quarter 2017 Financial Results Conference Call On November 13, 2017

RedHill Biopharma Announces EnteraGam® Poster Presentation At The ISPOR 20th Annual European Congress

RedHill Biopharma Announces EnteraGam® Poster Presentation At The ISPOR 20th Annual European Congress

RedHill Biopharma And IntelGenx Submit New Drug Application To FDA For RIZAPORT® For Migraines

RedHill Biopharma And IntelGenx Submit New Drug Application To FDA For RIZAPORT® For Migraines

RedHill Biopharma To Present At The BIO-Europe 2017 Conference

RedHill Biopharma To Present At The BIO-Europe 2017 Conference

RedHill Biopharma Receives Notice Of Allowance For A New U.S. Patent Covering RHB-104

RedHill Biopharma Receives Notice Of Allowance For A New U.S. Patent Covering RHB-104

Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers

Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers

The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.

RedHill Biopharma Receives FDA Orphan Drug Designation For MESUPRON For Pancreatic Cancer

RedHill Biopharma Receives FDA Orphan Drug Designation For MESUPRON For Pancreatic Cancer

RedHill Biopharma Announces Poster Presentation At The 2017 AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Conference

RedHill Biopharma Announces Poster Presentation At The 2017 AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Conference

RedHill Biopharma To Present At The BioNetwork 2017 Partnering Summit

RedHill Biopharma To Present At The BioNetwork 2017 Partnering Summit

RedHill Biopharma Announces Positive Top-Line Results From Phase II Study Of BEKINDA® In Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

RedHill Biopharma Announces Positive Top-Line Results From Phase II Study Of BEKINDA® In Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Load More
Quant Rating on 3:59 PM EDT 8/23/2019

D-

(Sell)

From Our Partners

RedHill And Talicia In H. Pylori: The PDUFA Countdown
SeekingAlpha

RedHill files for $150M shelf offering
SeekingAlpha

RedHill inks $60M ADS sales deal with Leerink; shares down 10%
SeekingAlpha

RedHill EPS beats by $0.31, misses on revenue
SeekingAlpha

RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities
The Fly

RDHL, SFIX among premarket gainers
SeekingAlpha

Oppenheimer likes Fate Therapeutics in premarket analyst action
SeekingAlpha

RedHill Bio's Talicia nabs accelerated review status for H. pylori infection
SeekingAlpha

RedHill nabs U.S. patent covering RHB-104 and RHB-204
SeekingAlpha

RedHill Biopharma And Talicia: The NDA
SeekingAlpha

RedHill files U.S. application for combo antibiotic for H. pylori infection
SeekingAlpha

RedHill beats by $0.32, misses on revenue
SeekingAlpha

Redhill Biopharma (RDHL) Presents At H.C. Wainwright & Co. Annual Global Life Sciences Conference - Slideshow
SeekingAlpha

Redhill Biopharma (RDHL) Presents At 31st Annual ROTH Conference - Slideshow
SeekingAlpha

RedHill And Talicia In Helicobacter Pylori Eradication And The Market Assessment
SeekingAlpha
TheStreet Quant Rating: D- (Sell)

Get the (RDHL)
Report Here

Free Reports

Watchlist